Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.36
SCMP's Cash to Debt is ranked higher than
71% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.19 vs. SCMP: 1.36 )
SCMP' s 10-Year Cash to Debt Range
Min: 0.86   Max: No Debt
Current: 1.36

Equity to Asset 0.49
SCMP's Equity to Asset is ranked higher than
58% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SCMP: 0.49 )
SCMP' s 10-Year Equity to Asset Range
Min: -0.21   Max: 0.82
Current: 0.49

-0.21
0.82
Interest Coverage 4.86
SCMP's Interest Coverage is ranked higher than
51% of the 490 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.05 vs. SCMP: 4.86 )
SCMP' s 10-Year Interest Coverage Range
Min: 3.55   Max: 9999.99
Current: 4.86

3.55
9999.99
F-Score: 4
Z-Score: 4.16
M-Score: -2.08
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 8.76
SCMP's Operating margin (%) is ranked higher than
74% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.96 vs. SCMP: 8.76 )
SCMP' s 10-Year Operating margin (%) Range
Min: -903.97   Max: 28.03
Current: 8.76

-903.97
28.03
Net-margin (%) 6.24
SCMP's Net-margin (%) is ranked higher than
74% of the 786 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.39 vs. SCMP: 6.24 )
SCMP' s 10-Year Net-margin (%) Range
Min: -906.55   Max: 41.39
Current: 6.24

-906.55
41.39
ROE (%) 9.84
SCMP's ROE (%) is ranked higher than
82% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.37 vs. SCMP: 9.84 )
SCMP' s 10-Year ROE (%) Range
Min: -130.02   Max: 154.11
Current: 9.84

-130.02
154.11
ROA (%) 4.16
SCMP's ROA (%) is ranked higher than
75% of the 814 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. SCMP: 4.16 )
SCMP' s 10-Year ROA (%) Range
Min: -83.83   Max: 37.89
Current: 4.16

-83.83
37.89
ROC (Joel Greenblatt) (%) 21.48
SCMP's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 810 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.57 vs. SCMP: 21.48 )
SCMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19500.5   Max: 5678.08
Current: 21.48

-19500.5
5678.08
Revenue Growth (%) 12.50
SCMP's Revenue Growth (%) is ranked higher than
79% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. SCMP: 12.50 )
SCMP' s 10-Year Revenue Growth (%) Range
Min: -21.1   Max: 127
Current: 12.5

-21.1
127
» SCMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

SCMP Guru Trades in Q2 2013

Jim Simons 235,000 sh (+12.87%)
Steven Cohen Sold Out
» More
Q3 2013

SCMP Guru Trades in Q3 2013

Jim Simons 127,800 sh (-45.62%)
» More
Q4 2013

SCMP Guru Trades in Q4 2013

Jim Simons 36,000 sh (-71.83%)
» More
Q1 2014

SCMP Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SCMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Sucampo Pharmaceuticals Inc

Weekly CEO Sells Highlight: Sucampo Pharmaceuticals Inc, Family Dollar Stores Inc, Nike Inc, Halliburton Company
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Sucampo Pharmaceuticals Inc., Family Dollar Stores Inc., Nike Inc. and Halliburton Company. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 56.50
SCMP's P/E(ttm) is ranked higher than
72% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.40 vs. SCMP: 56.50 )
SCMP' s 10-Year P/E(ttm) Range
Min: 5.44   Max: 115.73
Current: 56.5

5.44
115.73
P/B 5.07
SCMP's P/B is ranked higher than
62% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.26 vs. SCMP: 5.07 )
SCMP' s 10-Year P/B Range
Min: 0.97   Max: 9.99
Current: 5.07

0.97
9.99
P/S 3.72
SCMP's P/S is ranked higher than
70% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. SCMP: 3.72 )
SCMP' s 10-Year P/S Range
Min: 1.2   Max: 6.98
Current: 3.72

1.2
6.98
PFCF 99.50
SCMP's PFCF is ranked higher than
82% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SCMP: 99.50 )
SCMP' s 10-Year PFCF Range
Min: 3.68   Max: 346.4
Current: 99.5

3.68
346.4
EV-to-EBIT 41.56
SCMP's EV-to-EBIT is ranked higher than
73% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.26 vs. SCMP: 41.56 )
SCMP' s 10-Year EV-to-EBIT Range
Min: 0.8   Max: 66.7
Current: 41.56

0.8
66.7
Current Ratio 2.81
SCMP's Current Ratio is ranked higher than
77% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.28 vs. SCMP: 2.81 )
SCMP' s 10-Year Current Ratio Range
Min: 1.27   Max: 9.21
Current: 2.81

1.27
9.21
Quick Ratio 2.80
SCMP's Quick Ratio is ranked higher than
81% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. SCMP: 2.80 )
SCMP' s 10-Year Quick Ratio Range
Min: 1.27   Max: 9.21
Current: 2.8

1.27
9.21

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.57
SCMP's Price/Tangible Book is ranked higher than
67% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.76 vs. SCMP: 5.57 )
SCMP' s 10-Year Price/Tangible Book Range
Min: 1.16   Max: 11.29
Current: 5.57

1.16
11.29
Price/Median PS Value 1.23
SCMP's Price/Median PS Value is ranked higher than
72% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.24 vs. SCMP: 1.23 )
SCMP' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 2.61
Current: 1.23

0.7
2.61
Price/Graham Number 3.91
SCMP's Price/Graham Number is ranked higher than
72% of the 836 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.69 vs. SCMP: 3.91 )
SCMP' s 10-Year Price/Graham Number Range
Min: 0.95   Max: 5.32
Current: 3.91

0.95
5.32
Earnings Yield (Greenblatt) 2.40
SCMP's Earnings Yield (Greenblatt) is ranked higher than
62% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. SCMP: 2.40 )
SCMP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.5   Max: 119.5
Current: 2.4

1.5
119.5
Forward Rate of Return (Yacktman) 1.36
SCMP's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.19 vs. SCMP: 1.36 )
SCMP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.4   Max: 2.4
Current: 1.36

0.4
2.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:R3A.Germany
Sucampo Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders for which there are unmet or underserved medical needs and commercial potential. The therapeutic potential of prostones was first identified by one of the company's founders. Two prostone-based products have received marketing approval: Amitiza for the treatment of chronic idiopathic constipation in adults and irritable bowel syndrome with constipation in adult women and Rescula for the treatment of glaucoma. Sucampo is mainly responsible for Amitiza research and development efforts and are the holder of the new drug application. Takeda is mainly responsible for the marketing and commercialization of Amitiza in the United States and Canada and markets Amitiza to office-based specialty physicians and primary care physicians in the United States and funds a portion of the research and development activities. Sucampo is currently pursuing marketing approval for Amitiza for opioid-induced bowel dysfunction in patients with non-malignant pain, a constipation-related gastrointestinal indication. Opioid pain relievers are prescribed for patients with chronic and acute pain, many of whom also develop opioid-induced bowel dysfunction. Sucampo is developing other prostone-based compounds for the treatment of a range of diseases. The most advanced of these programs are: Cobiprostone is currently in a phase 2 clinical trial for the prevention of ulcers induced by non-steroidal anti-inflammatory drugs. SPI-017 is being researched as a treatment of peripheral arterial and vascular disease and central nervous system disorders. Sucampo is developing the prostone compound cobiprostone for oral administration to treat various gastrointestinal and liver disorders, including NSAID-induced ulcers and portal hypertension.
» More Articles for SCMP

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: VeriFone Systems Inc, Northeast Utilities, Sucampo Pharmaceuticals Inc, Jan 26 2014 
Weekly CEO Sells Highlight: Sucampo Pharmaceuticals Inc, Family Dollar Stores Inc, Nike Inc, Hallibu Oct 21 2013 
comment on SCMP Mar 06 2013 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 08 2011 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 03 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) May 10 2010 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 06 2009 
Sucampo Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 07 2009 
Sucampo Pharmaceuticals Reports Financial Results for the Second Quarter of 2009 Aug 06 2009 


More From Other Websites
Sucampo/Takeda Amend Collaboration Agreement for Amitiza Oct 15 2014
SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Oct 14 2014
Sucampo Announces Extension of AMITIZA(R) (lubiprostone) License and Collaboration Agreement With... Oct 14 2014
Sucampo Enters into Settlement Agreement for Amitiza Oct 13 2014
Strength Seen in Sucampo (SCMP): Stock Rises 9.4% Oct 13 2014
Clinical Data for AMITIZA(R) Lubiprostone to be Presented at the American College of... Oct 13 2014
SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events Oct 10 2014
Vertex Pharmaceuticals (VRTX) Updates on Kalydeco Studies Oct 10 2014
Sucampo Pharma upgraded by Maxim Group Oct 10 2014
R-Tech Ueno: Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA® and... Oct 10 2014
SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Oct 09 2014
Sucampo Announces Settlement Agreement That Resolves Patent Litigation in U.S. Related to AMITIZA Oct 09 2014
Novartis Collaborates with Bristol-Myers Squibb Oct 07 2014
Sunesis Pharmaceuticals Down on Failure of Trial on Qinprezo Oct 07 2014
SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Oct 06 2014
Sucampo Announces Departure of Chief Financial Officer Oct 06 2014
Progenics/Salix's Relistor Label Expanded in the U.S. Oct 02 2014
Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA(R) (lubiprostone) for... Sep 29 2014
SUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Sep 17 2014
FDA approves AstraZeneca, Nektar constipation drug Sep 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK